← Browse by Condition
Medical Condition
her2 positive breast cancer
Total Trials
12
Recruiting Now
12
Trial Phases
Phase 1, Phase 2, Phase 3
NCT05378464 Phase 1
Recruiting
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
Enrollment
28 pts
Location
United States
Sponsor
H. Lee Moffitt Cancer Center a...
NCT04481932 Phase 2
Recruiting
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
Enrollment
104 pts
Location
China
Sponsor
Peking University
NCT06313086 Phase 3
Recruiting
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
Enrollment
442 pts
Location
China
Sponsor
CSPC ZhongQi Pharmaceutical Te...
NCT06693037
Recruiting
Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
Enrollment
2,092 pts
Location
China
Sponsor
Shu Wang
NCT06172127 Phase 2
Recruiting
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
Enrollment
165 pts
Location
United States, Franc...
Sponsor
MedSIR
NCT04638725
Recruiting
Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer
Enrollment
9,000 pts
Location
France
Sponsor
Institut de cancérologie Stras...
NCT06123988
Recruiting
Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer
Enrollment
260 pts
Location
United States
Sponsor
University of Miami
NCT06253871 Phase 1
Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Enrollment
243 pts
Location
United States, Franc...
Sponsor
Iambic Therapeutics, Inc
NCT04886531 Phase 2
Recruiting
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Enrollment
30 pts
Location
United States
Sponsor
Ruth O'Regan
NCT06958627 Phase 2, Phase 3
Recruiting
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
Enrollment
964 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
NCT06217185 Phase 4
Recruiting
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Enrollment
100 pts
Location
China
Sponsor
Hebei Medical University Fourt...
NCT04585750 Phase 1, Phase 2
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Enrollment
300 pts
Location
United States, Austr...
Sponsor
PMV Pharmaceuticals, Inc